GHK-Cu (copper peptide) side effects reported in available literature include localized injection site reactions, mild systemic inflammation markers, and rare allergic responses
Is GHK-Cu for skincare or cosmetic use
Based on the phase 2 and phase 3 trial protocols: Weeks 1-4: 1 mg once weekly Weeks 5-8: 2 mg once weekly Weeks 9-12: 4 mg once weekly Weeks 13-16: 8 mg once weekly Weeks 17 onward: 12 mg once weekly (maximum dose) The starting dose of retatrutide is deliberately low because the triple-agonist mechanism produces more intense initial side effects than single-pathway compounds
Davies-Jenkins, View ORCID ProfileHelge J
Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020
6(12):94453 Cawley J, Biener A, Meyerhoefer C, Ding Y, Zvenyach T, Smolarz BG et al (2021) Direct medical costs of obesity in the United States and the most populous states